Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Voyageur Pharmaceuticals Ltd > Well
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(78)
•••
Comment by postie1on Mar 01, 2024 3:21pm
79 Views
Post# 35910080

RE:RE:RE:RE:RE:Well

RE:RE:RE:RE:RE:WellThese 2 old press releases should answer that question. Fully read these carefully and look at that pipeline chart on th VM website. The 2 Iodine products are in the same stage as the 4 Barium products. I think the 1st product woke them up to the fact that it has to be a full suite to convince buyers to buy from VM to prevent a bad situation for the buyers. These other companies will not go down without a fight so buyers have to protect themselves from hardballing tactics.

2020-02-26 | TSXV:VM | Press Release | Voyageur Pharmaceuticals Ltd (stockhouse.com)

2020-07-27 | TSXV:VM | Press Release | Voyageur Pharmaceuticals Ltd (stockhouse.com)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities